Figure 3.

AIMS platform provides favorable characteristics for antitumor immune response: lyophilizable formulation, in situ depot formation, and migration into TDLN. a) Redispersion and suction of lyophilized AIMS by 21 G syringe. b) Mean size of various AIMS containing each drug (n = 5). c) TEM image of AIMS platform and lyophilized AIMS (scale bar = 200 nm). d) Drug delivery characteristics: in situ depot formation in TME and efficient migration into TDLN. Fluorescence images depicting e) the lymph node of mice separated 0, 6, 24, 48, and 72 h after injection and f) retention of DiD around the injection site 0, 3, 12, 24, 48, and 72 h after injection. The mice were treated with 50 µL of PBS, 10 mg mL⁻¹ DiD dye‐containing solution, or the same concentration of DiD‐containing AIMS intratumorally 5 d after tumor inoculation. Data are presented as the mean ± SD. P values were determined by Student's t test at the endpoint (ns, not significant).